PUBLISHER: The Business Research Company | PRODUCT CODE: 1509631
PUBLISHER: The Business Research Company | PRODUCT CODE: 1509631
Endocrine testing involves the diagnostic assessment of hormone levels within the body, typically conducted through blood, urine, or saliva analyses, to evaluate the function of the endocrine system. These tests play a vital role in diagnosing a range of endocrine disorders, such as diabetes, thyroid disorders, adrenal insufficiency, and pituitary gland disorders, enabling healthcare providers to formulate appropriate treatment and management plans for affected patients.
The primary types of endocrine testing encompass various assessments including the estradiol (E2) test, follicle-stimulating hormone (FSH) test, human chorionic gonadotropin (HCG) hormone test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid-stimulating hormone (TSH) test, prolactin test, among others. For instance, the Estradiol (E2) Test involves a blood test to measure estradiol levels in the body. These tests utilize diverse technologies such as tandem mass spectrometry, immunoassays, monoclonal and polyclonal antibody technologies, sensor technology, clinical chemistry, among others, and are commonly conducted in hospitals, clinical laboratories, diagnostic centers, and similar healthcare facilities.
The endocrine testing market research report is one of a series of new reports from The Business Research Company that provides endocrine testing market statistics, including endocrine testing industry global market size, regional shares, competitors with a endocrine testing market share, detailed endocrine testing market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine testing industry. This endocrine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The endocrine testing market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed in the historical period can be attributed to several key factors, including the discovery of hormones and endocrine pathways, the standardization of diagnostic tests, the implementation of public health initiatives, and the increased advocacy and empowerment of patients.
The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forecast period can be attributed to various factors, including the growing prevalence of endocrine disorders, heightened defense spending, an aging population, increased awareness and early diagnosis initiatives, and heightened overall awareness regarding endocrine health. Key trends expected in the forecast period encompass advancements in biomarker detection techniques, the integration of omics technologies, the utilization of artificial intelligence and machine learning for diagnostic purposes, a focus on quality assurance and standardization measures, and an emphasis on collaborative research efforts and translational medicine approaches.
The upward trend in diabetes prevalence is anticipated to drive the growth of the endocrine testing market in the foreseeable future. Diabetes, a condition characterized by elevated blood sugar levels, is on the rise due to various factors such as unhealthy dietary patterns, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine testing plays a crucial role in diabetes management, encompassing tests such as hemoglobin A1c, fasting plasma glucose, and C-peptide tests to diagnose the condition, monitor glucose levels, and evaluate insulin production and sensitivity. For instance, data from the International Diabetes Federation in 2021 revealed that approximately 537 million adults (aged 20-79 years) globally were living with diabetes. Projections indicate a further increase to 643 million by 2030 and 783 million by 2045. Consequently, the surge in diabetes prevalence is stimulating demand within the endocrine testing market.
Key players in the endocrine testing market are focusing on developing point-of-care testing solutions to enhance accessibility and efficiency in diagnosing endocrine disorders. Point-of-care testing enables rapid results, aiding in prompt diagnosis and management of conditions such as heart failure in patients displaying symptoms such as shortness of breath and fatigue. For example, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced a point-of-care NT-proBNP test in India. This test is specifically tailored for screening diabetes patients at risk of cardiovascular diseases such as heart failure (HF), facilitating early detection and intervention. It empowers clinicians to identify high-risk T2D patients promptly and initiate timely treatment discussions, ultimately leading to improved outcomes and patient well-being.
In October 2022, Tolmar, a US-based pharmaceutical company, acquired Jatenzo from Clarus Therapeutics, although the financial details remain undisclosed. This acquisition aligns with Tolmar's focus on pediatric endocrinology and men's health, augmenting their portfolio of specialty pharmaceutical products. Clarus Therapeutics, a US-based pharmaceutical company, specializes in developing and commercializing therapies for individuals with endocrine disorders.
Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMerieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.
North America was the largest region in the endocrine testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the endocrine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The endocrine testing market consists of revenues earned by entities by providing services such as hormone level testing, thyroid function testing, diabetes testing, adrenal function testing, reproductive hormone testing, pituitary function testing, and bone metabolism testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine testing market also includes sales of assay kits, analyzers, point-of-care testing devices, reagents, software solutions, quality control materials, and calibrators and controls. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Endocrine Testing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on endocrine testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for endocrine testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endocrine testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.